Articles tagged with: Myeloma Morning
News»

Hello again, myeloma world.
Today's review of myeloma-related research and news covers a particularly wide range of topics.
We start our review with a quick look at a new study related to Pomalyst and its use in heavily pretreated multiple myeloma patients. (The Beacon published a separate article about this study earlier today.)
Next, we report on changes the U.S. Food and Drug Administration has made in the procedures for “compassionate use” access to unapproved drug treatments, including potential new myeloma therapies.
We then turn to discussion of a European study …
News»

How has your week been, myeloma world?
Summer definitely is here at Myeloma Morning Headquarters. We had temperatures yesterday and today that rival those normally seen in early August.
We're not exactly sure how we feel about this development.
As for myeloma-related news, we have a lot of ground to cover.
We have one new myeloma research study that we summarize at length. It's about a difficult subject, namely, the impact of early relapse on the overall survival of multiple myeloma patients. It's a difficult subject because, not surprisingly, early relapse continues …
News»

Good morning, myeloma world.
We hope you had a pleasant weekend and that your new week is off to a good start.
The big news today is that Darzalex (daratumumab) has been approved in Europe as a new treatment for multiple myeloma. We will be publishing a separate news article on the approval, which was announced a few hours ago. In the meantime, you can find information about the approval in this press release from Genmab, the company that initially developed Darzalex.
The other news we have for you …
News»

Good morning, myeloma world.
Since the last edition of Myeloma Morning, abstracts for two important upcoming medical meetings have been made public: the American Society of Clinical Oncology (ASCO) annual meeting, which will take place June 3 through June 7 in Chicago, and the European Hematology Association (EHA) annual congress, which is scheduled for June 9 through June 12 in Copenhagen, Denmark.
The publication of the abstracts and the meetings themselves mean that there is going to be a lot of multiple myeloma-related news in the coming weeks. We will do our …
News»

Hello, myeloma world.
We hope your week has gotten off to a great start.
We're looking forward to reviewing three new myeloma-related research studies with you today.
The first study we summarize in today's report focuses on the survival of older blood cancer patients, including (of course) older multiple myeloma patients.
The second study presents the results of the CHAMPION-1 clinical trial, which tested once weekly Kyprolis in combination with dexamethasone in relapsed multiple myeloma patients.
The final study we review is a detailed look at an important Revlimid-related side effect – …
News»

It's good to see you again, myeloma world.
We got tied up the past couple days with, among other things, coverage of the Empliciti approval in Europe. But we're glad to be back and we have two new research studies that we'd like to discuss with you.
First, we take a look at an Israeli study that does a deep dive into the t(11;14) chromosomal abnormality in newly diagnosed multiple myeloma patients. The focus of this particular deep dive is the impact other chromosomal abnormalities have on the prognosis of newly …
News»

How has your week started, myeloma world?
We hope it's going well so far.
We once again have a rather long list of new myeloma research we'd like to discuss with you. We suspect most of our readers will find at least one or two studies in the report to be of particular interest.
We begin today's report with a discussion of a somewhat rare eye-related side effect of Velcade (bortezomib) and a possible way to control the side effect.
Next, we take a quick look at two articles about …